High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden

Figures & data

Figure 1. Effectiveness with 95% confidence interval (CI) of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 3 (1–14 February 2021) and 4 (15–28 February 2021).

Table 1. Baseline characteristics of the study cohort on 27 December 2020 when COVID-19 vaccination started, stratified by vaccination status on 28 February 2021.

	Vaccinated (n = 26,587)	Unvaccinated (n = 779,154)	Uptake (% of total) (3.3)
Sex, n (%)
Female	21,274 (80.0)	404,808 (52.0)	5.4
Male	5,313 (20.0)	374,346 (48.0)	1.3
Age by sex, n (%)
Female
18–44	8,947 (33.7)	223,877 (28.7)	3.8
45–49	2,711 (10.2)	40,405 (5.2)	6.3
50–54	3,097 (11.6)	39,870 (5.1)	7.2
55–59	3,572 (13.4)	37,283 (4.8)	8.7
60–64	2,947 (11.1)	32,911 (4.2)	8.2
Male
18–44	2,854 (10.7)	239,332 (30.7)	1.2
45–49	541 (2.0)	44,580 (5.7)	1.2
50–54	554 (2.1)	43,876 (5.6)	1.2
55–59	644 (2.4)	41,427 (5.3)	1.5
60–64	720 (2.7)	35,593 (4.6)	2.0
Country of birth
Sweden	20,725 (78.0)	547,873 (70.3)	3.6
Abroad	5,862 (22.0)	231,281 (29.7)	2.5
Civil status
Unmarried	10,088 (37.9)	380,434 (48.8)	2.6
Married	12,066 (45.4)	307,642 (39.5)	3.8
Divorced	4,065 (15.3)	85,723 (11.0)	4.5
Widow/widower	368 (1.4)	5,355 (0.7)	6.4
Positive SARS-CoV-2 test before 27 December 2020	2,660 (10.0)	36,740 (4.7)	6.8

Table 2. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 4 (15–28 February 2021).

	Cases, n	Person-time, weeks	Incidence (95% CI)^a	Effectiveness, % (95% CI)
No prior positive test
Unvaccinated or before 1st dose	4,155	1,414,660	294 (285–303)	Reference^b
1st dose, day 0–13	9	2,260	398 (138–658)	Not evaluated
1st dose, day 14–	25	14,690	170 (103–237)	42 (14–63)
2nd dose, day 0–6	10	8,537	117 (45–190)	60 (27–81)
2nd dose, day 7–	8	19,088	42 (13–71)	86 (72–94)
Prior positive test^c
Unvaccinated or before 1st dose	21	75,399	28 (16–40)	91 (85–94)

^aCases per 100,000 persons and week (95% confidence interval). Results from statistical analysis were weighted with respect to sex and age distribution of the vaccinated cohort.

^bReference category in the calculation of vaccine effectiveness.

^cThe number of vaccinated with prior positive test was too few to permit evaluation of vaccine effectiveness.